#

COPD

  • Compensation to be determined
  • 13 visits (enrollment open)
#

18+ Years

#
Male or Female
#
Smoker & Non-Smoker

Description

This is a phase III, multinational, multicenter, randomized, double-blind, 2-arm parallel group study. Comparing efficacy, safety and tolerability of the fixed dose triple combination of Beclomethasone Dipropionate/Fluticasone Furoate/Glycopyrronium Bromide 100/6/12.5µg with the fixed dose dual combination of Beclomethasone Dipropionate/Fluticasone Furoate 100/6µg. The study will last approximately 55 weeks for each subject.

Is this not what you are looking for?
Check out our other studies.

Related Studies

#

Chronic Idiopathic Urticaria

  • Compensation to be determined
  • 13 clinic visits including 3 safety follow-up visits
#
Between 18 - 75 Years

#
Male or Female
#
Smoker & Non-Smoker
#

Ulcerative Colitis (IQVIA)

  • Compensation to be determined
  • clinic visits 10
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
#

COPD

  • Compensation to be determined
  • 12 clinic visits
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
© 2024 Access Research Institute. All Rights Reserved